| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.04B | 1.00B | 1.12B | 971.52M | 733.38M |
| Gross Profit | 144.27M | 160.03M | 141.02M | 90.55M | 110.54M |
| EBITDA | 107.02M | 101.90M | 93.96M | 63.44M | 74.02M |
| Net Income | 40.51M | 19.87M | 26.62M | 3.43M | 24.36M |
Balance Sheet | |||||
| Total Assets | 720.67M | 524.89M | 607.09M | 611.40M | 531.55M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 0.00 | 0.00 | -28.09M | -25.07M |
| Total Debt | 223.30M | 85.13M | 117.30M | 122.14M | 90.39M |
| Total Liabilities | 436.62M | 245.94M | 320.07M | 324.42M | 227.20M |
| Stockholders Equity | 283.81M | 278.55M | 286.83M | 286.79M | 304.38M |
Cash Flow | |||||
| Free Cash Flow | 60.82M | 40.49M | 59.89M | 56.86M | 56.70M |
| Operating Cash Flow | 74.25M | 66.92M | 80.55M | 63.99M | 64.49M |
| Investing Cash Flow | -163.70M | 6.82M | -24.05M | -49.84M | -7.99M |
| Financing Cash Flow | 89.45M | -73.74M | -56.50M | -14.15M | -56.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | C$867.30M | 30.99 | 6.36% | 1.98% | 3.69% | 92.38% | |
64 Neutral | C$738.97M | 17.94 | 14.45% | 3.02% | -0.73% | 221.74% | |
64 Neutral | C$444.19M | 23.08 | 8.31% | 3.43% | 26.29% | -6.47% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Dexterra Group Inc. will release its fourth-quarter 2025 financial results on March 3, 2026, after markets close, followed by a conference call and webcast the next morning to review the results. The scheduled disclosure and investor call underscore the company’s efforts to maintain transparency with stakeholders and provide insight into recent operational performance and market positioning.
Investors and analysts will be able to access a results presentation on Dexterra’s investor relations website, join the live webcast, or listen to a recorded version of the call available for a limited time. This structured communication process is intended to facilitate broad access to the company’s financial and strategic updates, which may inform market expectations and stakeholder assessments of Dexterra’s trajectory.
The most recent analyst rating on (TSE:DXT) stock is a Buy with a C$14.50 price target. To see the full list of analyst forecasts on Dexterra Group stock, see the TSE:DXT Stock Forecast page.